两种聚乙二醇干扰素分别联合利巴韦林治疗丙型病毒性肝炎疗效分析

The efficacy of two pegylated interferon separately combined with Ribavirin in the treatment of hepatitis C virus infection

目的探讨聚乙二醇α-2a干扰素联合利巴韦林及聚乙二醇α-2b干扰素联合利巴韦林治疗丙型肝炎的疗效。方法选取本院收治的丙型肝炎病例120例,分为派罗欣组及佩乐能组,每组60例,派罗新组给予聚乙二醇α-2a干扰素联合利巴韦林治疗,佩乐能组给予聚乙二醇α-2b干扰素联合利巴韦林治疗,对两组患者病毒学应答及副作用进行统计分析。结果派罗欣组患者RVR率71.67%,EVR率91.67%,SVR率91.67%,流感样症状83.33%,腹泻21.67%,粒细胞下降68.33%,脱发11.67%,甲状腺功能异常18.33%。佩乐能组患者RVR率73.33%,EVR率90.00%,SVR率90.00%,流感样症状68.33%,腹泻23.33%,粒细胞下降66.7%,脱发13.33%,甲状腺功能异常16.67%。两组患者RVR、EVR、SVR率无统计学差异,而流感样症状佩乐能相对较少,差异有统计学意义(P<0.05),腹泻、粒细胞下降、脱发及甲状腺功能异常,差异无统计学意义(P>0.05)。结论派罗欣及佩乐能联合利巴韦林治疗丙型肝炎疗效等同。目前两种长效干扰素分别联合利巴韦林仍然可以作为丙型肝炎治疗的首选方法之一。

Objective To investigate the efficacy of PEG-IFN α-2a combined with ribavirin and PEG- IFN α -2b combined with ribavirin in the treatment of hepatitis C. Method In this study,the clinical data of 120 cases of patients with hepatitis C in our hospital were selected and divided into pegasys group and peglntron group,60 cases in each group.The pegasys group was treated with pegylated interferon alpha -2a eombined with ribavirin.The pegIntron group was treated with pegylated interferon-2b combined with ribavirin.The virological response and side effects of the two groups were statistically analyzed. Results In pegasys group,the RVR rate was 71.67%,the EVR rate was 91.67%,the SVR rate was 91.67%,the flu like symptoms were 83.33%,diarrhea 21.67%,granulocytes decreased 68.33%,alopecia 11.67%,and thyroid dysfunction 18.33%.In pegIntron group RVR rate was 73.33%,EVR rate was 90%,SVR rate was 90%,flu like symptoms were 68.33%,diarrhea was 23.33%,granulocytes decreased by 66.7%,hair loss was 13.33%,and thyroid function was abnormal 16.67%.The differences of RVR,EVR,SVR rate and flu like symptoms between the two groups were statistically significant （P 〈 0.05）,and there was no significant difference in diarrhea,granulocyte drop,alopecia and thyroid dysfunction （P 〉 0.05）. Conclusion The efficacy of pegasys and pegIntron in the treatment of hepatitis C is equivalent.At present,the combination of the two long-acting interferon combined with Leigh Bhave Lin can still be used as the first choice for the treatment of hepatitis C.